Cromos Pharma, where the patients are

MedImmune

MD Anderson, MedImmune collaborate on cancer immunotherapy

Monday, March 17, 2014 01:42 PM

The University of TexasMD Anderson Cancer Center and MedImmune, the global biologics R&D arm of AstraZeneca, will collaborate through MD Anderson's Moon Shots Program to develop therapies that unleash patients' immune systems to attack their cancers.

More... »

CRF Health eCOA webinar series

Medimmune, UC San Francisco collaborate

Friday, February 14, 2014 01:40 PM

MedImmune, the global biologics R&D arm of AstraZeneca, has entered a three-year collaboration with the Clinical and Translational Science Institute (CTSI) at the University of California, San Francisco (UCSF).  The collaboration will focus on CTSI's Catalyst Awards program, which solicits applications from University scientists who wish to move their translational research beyond the bench and into product development.

More... »


James Brown elected to Safe-Biopharma board of directors

Friday, February 14, 2014 01:18 PM

SAFE-BioPharma Association, the nonprofit collaboration that developed and manages the global SAFE-BioPharma digital identity and digital signature standard, has elected James W. Brown, Ph.D., chief operating officer, Regenx Biosciences to its board of directors.

More... »

MedImmune, Immunocore enter immunotherapy agreement

Wednesday, January 8, 2014 01:21 PM

MedImmune, AstraZeneca’s global biologics R&D arm, has entered into an oncology research collaboration and licensing agreement with Immunocore, a privately-held, U.K.-based biotechnology company. Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilizing Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology.

More... »

MedImmune acquires Spirogen, collaborates with ADC Therapeutics

Monday, October 21, 2013 01:39 PM

MedImmune, the global biologics R&D arm of AstraZeneca, has acquired Spirogen, a privately-held biotech company focused on antibody-drug conjugate technology for use in oncology.

More... »

MedImmune completes acquisition of Amplimmune

Monday, October 7, 2013 02:52 PM

MedImmune, the global biologics R&D arm of AstraZeneca, completed its acquisition of Amplimmune, a privately-held, U.S.-based biologics company focused on developing novel therapeutics in cancer immunology.

More... »

PPD names VP for global product development

Monday, September 23, 2013 01:30 PM

CRO PPD has appointed Gregory Dennis, M.D., vice president of global product development. Dennis will be therapeutic area head, providing medical and scientific expertise for rheumatology, immunology and inflammatory diseases.

More... »

Ambrx names Peter Kiener chief scientific officer

Wednesday, August 28, 2013 02:42 PM

Ambrx, a clinical stage biopharmaceutical company, has appointed Peter Kiener, Ph.D., chief scientific officer. Kiener has experience in the development of next-generation biologic therapeutics, including multi-specific, antibody based biologics, while president, chief executive officer and cofounder of Zyngenia.

Kiener led Zyngenia through its early stages of development, including validating the technology platform, identifying and advancing lead programs and securing Series A funding. Previously, Kiener was the executive vice president and global head of biologics R&D at MedImmune, AstraZeneca's biologics arm. He built protein and antibody engineering capabilities and oversaw the submission of multiple INDs and NDAs. Over the previous 18 years, Kiener held multiple positions at Bristol-Myers Squibb, 10 of which were spent working on biological therapeutics.

More... »

MedImmune acquires Amplimmune

Monday, August 26, 2013 12:24 PM

AstraZeneca has announced that MedImmune, its global biologics R&D arm, has agreed to acquire Amplimmune, a privately-held, Maryland-based biologics company focused on developing novel therapeutics in cancer immunology.

More... »

Vivus board appoints new chairman, CEO

Wednesday, July 24, 2013 03:00 PM

Biopharmaceutical company Vivus’ board of directors has appointed Michael Astrue chairman and Anthony Zook chief executive officer.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs